FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385851408> ?p ?o ?g. }

• W4385851408 endingPage "17980" @default.
• W4385851408 startingPage "17967" @default.
• W4385851408 abstract "Anti-PD-1-based immunotherapy is considered a preferred first-line treatment for advanced BRAF V600-mutant melanoma. However, a recent international multi-center study suggested that the efficacy of immunotherapy is poorer in Asian patients in the non-acral cutaneous subtype. We hypothesized that the optimal first-line treatment for Asian patients may be different.We retrospectively collected data of Asian patients with advanced BRAF V600-mutant melanoma treated with first-line BRAF/MEK inhibitors (BRAF/MEKi), anti-PD-1 monotherapy (Anti-PD-1), and nivolumab plus ipilimumab (PD-1/CTLA-4) between 2016 and 2021 from 28 institutions in Japan.We identified 336 patients treated with BRAF/MEKi (n = 236), Anti-PD-1 (n = 64) and PD-1/CTLA-4 (n = 36). The median follow-up duration was 19.9 months for all patients and 28.6 months for the 184 pa tients who were alive at their last follow-up. For patients treated with BRAF/MEKi, anti-PD-1, PD-1/CTLA-4, the median ages at baseline were 62, 62, and 53 years (p = 0.03); objective response rates were 69%, 27%, and 28% (p < 0.001); median progression-free survival (PFS) was 14.7, 5.4, and 5.8 months (p = 0.003), and median overall survival (OS) was 34.6, 37.0 months, and not reached, respectively (p = 0.535). In multivariable analysis, hazard ratios (HRs) for PFS of Anti-PD-1 and PD-1/CTLA-4 compared with BRAF/MEKi were 2.30 (p < 0.001) and 1.38 (p = 0.147), and for OS, HRs were 1.37 (p = 0.111) and 0.56 (p = 0.075), respectively. In propensity-score matching, BRAF/MEKi showed a tendency for longer PFS and equivalent OS with PD-1/CTLA-4 (HRs for PD-1/CTLA-4 were 1.78 [p = 0.149]) and 1.03 [p = 0.953], respectively). For patients who received second-line treatment, BRAF/MEKi followed by PD-1/CTLA-4 showed poor survival outcomes.The superiority of PD-1/CTLA-4 over BRAF/MEKi appears modest in Asian patients. First-line BRAF/MEKi remains feasible, but it is difficult to salvage at progression. Ethnicity should be considered when selecting systemic therapies until personalized biomarkers are available in daily practice. Further studies are needed to establish the optimal treatment sequence for Asian patients." @default.
• W4385851408 created "2023-08-17" @default.
• W4385851408 creator A5001893646 @default.
• W4385851408 creator A5002517892 @default.
• W4385851408 creator A5002901596 @default.
• W4385851408 creator A5003381260 @default.
• W4385851408 creator A5004693750 @default.
• W4385851408 creator A5012794894 @default.
• W4385851408 creator A5012922874 @default.
• W4385851408 creator A5017302973 @default.
• W4385851408 creator A5018248890 @default.
• W4385851408 creator A5022364870 @default.
• W4385851408 creator A5024200791 @default.
• W4385851408 creator A5024535565 @default.
• W4385851408 creator A5024688006 @default.
• W4385851408 creator A5025766838 @default.
• W4385851408 creator A5032007088 @default.
• W4385851408 creator A5033326805 @default.
• W4385851408 creator A5036766499 @default.
• W4385851408 creator A5039970331 @default.
• W4385851408 creator A5041859750 @default.
• W4385851408 creator A5042799216 @default.
• W4385851408 creator A5046150870 @default.
• W4385851408 creator A5047984722 @default.
• W4385851408 creator A5054498346 @default.
• W4385851408 creator A5058401075 @default.
• W4385851408 creator A5060263269 @default.
• W4385851408 creator A5068079253 @default.
• W4385851408 creator A5069878982 @default.
• W4385851408 creator A5073959767 @default.
• W4385851408 creator A5074767160 @default.
• W4385851408 creator A5076439143 @default.
• W4385851408 creator A5080001880 @default.
• W4385851408 creator A5081237441 @default.
• W4385851408 creator A5083738577 @default.
• W4385851408 creator A5090106746 @default.
• W4385851408 creator A5090501626 @default.
• W4385851408 date "2023-08-16" @default.
• W4385851408 modified "2023-10-12" @default.
• W4385851408 title "Systemic therapy for Asian patients with advanced <scp>BRAF V600</scp>‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan (<scp>B‐CHECK‐RWD</scp> study)" @default.
• W4385851408 cites W2600124489 @default.
• W4385851408 cites W2611187032 @default.
• W4385851408 cites W2692164552 @default.
• W4385851408 cites W2744598371 @default.
• W4385851408 cites W2753432434 @default.
• W4385851408 cites W2766903152 @default.
• W4385851408 cites W2774712455 @default.
• W4385851408 cites W2791686077 @default.
• W4385851408 cites W2897059317 @default.
• W4385851408 cites W2901290714 @default.
• W4385851408 cites W2910254477 @default.
• W4385851408 cites W2912374321 @default.
• W4385851408 cites W2917037937 @default.
• W4385851408 cites W2938997009 @default.
• W4385851408 cites W2948155539 @default.
• W4385851408 cites W2987654547 @default.
• W4385851408 cites W3041499190 @default.
• W4385851408 cites W3043703771 @default.
• W4385851408 cites W3080392435 @default.
• W4385851408 cites W3081553497 @default.
• W4385851408 cites W3088493402 @default.
• W4385851408 cites W3090469545 @default.
• W4385851408 cites W3094502178 @default.
• W4385851408 cites W3122239502 @default.
• W4385851408 cites W3126978842 @default.
• W4385851408 cites W3182981660 @default.
• W4385851408 cites W3195642548 @default.
• W4385851408 cites W4200001874 @default.
• W4385851408 cites W4200479769 @default.
• W4385851408 cites W4200548051 @default.
• W4385851408 cites W4220761090 @default.
• W4385851408 cites W4220824310 @default.
• W4385851408 cites W4220934153 @default.
• W4385851408 cites W4223911670 @default.
• W4385851408 cites W4224267512 @default.
• W4385851408 cites W4281635069 @default.
• W4385851408 cites W4282020990 @default.
• W4385851408 cites W4282925519 @default.
• W4385851408 cites W4294100626 @default.
• W4385851408 cites W4294710515 @default.
• W4385851408 cites W4295817732 @default.
• W4385851408 cites W4295821429 @default.
• W4385851408 cites W4296784206 @default.
• W4385851408 cites W4297339120 @default.
• W4385851408 cites W4303446545 @default.
• W4385851408 cites W4385851408 @default.
• W4385851408 doi "https://doi.org/10.1002/cam4.6438" @default.
• W4385851408 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37584204" @default.
• W4385851408 hasPublicationYear "2023" @default.
• W4385851408 type Work @default.
• W4385851408 citedByCount "1" @default.
• W4385851408 crossrefType "journal-article" @default.
• W4385851408 hasAuthorship W4385851408A5001893646 @default.
• W4385851408 hasAuthorship W4385851408A5002517892 @default.
• W4385851408 hasAuthorship W4385851408A5002901596 @default.
• W4385851408 hasAuthorship W4385851408A5003381260 @default.
• W4385851408 hasAuthorship W4385851408A5004693750 @default.
• W4385851408 hasAuthorship W4385851408A5012794894 @default.

• next